Literature DB >> 21216504

Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.

Gianfranco Balboni1, Severo Salvadori, Ewa D Marczak, Brian I Knapp, Jean M Bidlack, Lawrence H Lazarus, Xuemei Peng, Yu Gui Si, John L Neumeyer.   

Abstract

Bifunctional ligands containing an ester linkage between morphine and the δ-selective pharmacophore Dmt-Tic were synthesized, and their binding affinity and functional bioactivity at the μ, δ and κ opioid receptors determined. Bifunctional ligands containing or not a spacer of β-alanine between the two pharmacophores lose the μ agonism deriving from morphine becoming partial μ agonists 4 or μ antagonists 5. Partial κ agonism is evidenced only for compound 4. Finally, both compounds showed potent δ antagonism. Copyright Â
© 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21216504      PMCID: PMC3035428          DOI: 10.1016/j.ejmech.2010.12.001

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  26 in total

Review 1.  Regulation of opioid receptors by endocytic membrane traffic: mechanisms and translational implications.

Authors:  Mark von Zastrow
Journal:  Drug Alcohol Depend       Date:  2010-03-24       Impact factor: 4.492

2.  Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

3.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

4.  Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.

Authors:  Michael Decker; Brian S Fulton; Bin Zhang; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 5.  Multiple ligands in opioid research.

Authors:  Steven Ballet; Markus Pietsch; Andrew D Abell
Journal:  Protein Pept Lett       Date:  2008       Impact factor: 1.890

Review 6.  Kappa receptor bivalent ligands.

Authors:  Xuemei Peng; John L Neumeyer
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 7.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

Review 8.  In vivo trafficking of endogenous opioid receptors.

Authors:  Yulin Wang; Elisabeth J Van Bockstaele; Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2008-10-05       Impact factor: 5.037

Review 9.  Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.

Authors:  N Dietis; R Guerrini; G Calo; S Salvadori; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2009-05-27       Impact factor: 9.166

Review 10.  Design of multivalent ligand targeting G-protein-coupled receptors.

Authors:  Zhili Liu; Jing Zhang; Ao Zhang
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more
  7 in total

Review 1.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

Review 2.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

3.  Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

Authors:  M F Bird; R S Vardanyan; V J Hruby; G Calò; R Guerrini; S Salvadori; C Trapella; J McDonald; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2015-02-13       Impact factor: 9.166

4.  Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism.

Authors:  Deanna Montgomery; Jessica P Anand; Nicholas W Griggs; Thomas J Fernandez; Joshua G Hartman; Ashley A Sánchez-Santiago; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2019-07-01       Impact factor: 4.418

5.  Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.

Authors:  Ruben S Vardanyan; James P Cain; Saghar Mowlazadeh Haghighi; Vlad K Kumirov; Mary I McIntosh; Alexander J Sandweiss; Frank Porreca; Victor J Hruby
Journal:  J Heterocycl Chem       Date:  2016-06-01       Impact factor: 2.193

Review 6.  Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction.

Authors:  Robert Root-Bernstein
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-10

7.  Differential Effects of a Novel Opioid Ligand UTA1003 on Antinociceptive Tolerance and Motor Behaviour.

Authors:  Alok K Paul; Krystel L Woolley; Mohammed Rahmatullah; Polrat Wilairatana; Jason A Smith; Nuri Gueven; Nikolas Dietis
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.